Personalized Radiotherapy with Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer Using AI Classification
Led by German Oncology Center, Cyprus · Updated on 2026-09-15
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating a new way to personalize radiotherapy and androgen deprivation therapy ADT duration for men with high-risk localized prostate cancer. This single-arm, phase II study uses advanced artificial intelligence to classify patients and tailor treatment. The goal is to shorten ADT duration while maintaining effective disease control and potentially reducing side effects compared to current guidelines.
Participants will receive a combination of treatments starting with a high-dose-rate brachytherapy HDR BT boost to the prostate, delivering 15 Gray in a single fraction. After a break of about two weeks, they will undergo stereotactic body radiation therapy SBRT delivering 25 Gray in five daily fractions to the prostate and seminal vesicles. Alongside radiation, patients will take androgen deprivation therapy for 12 months, given concurrently and as an adjuvant.
During the study, participants will have regular assessments including imaging scans, biopsies, and quality of life questionnaires. Researchers will monitor disease-free survival at five years as the primary outcome, along with secondary measures such as local or regional failure, metastatic-free survival, overall survival, prostate cancer-specific survival, biochemical failure, and treatment-related toxicities. Testosterone recovery and quality of life will also be evaluated up to five years after treatment completion.
CONDITIONS
Brief Title
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
Research Team
E
Elena Pallari, PhD
K
Kristis Vevis, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Primary prostate cancer shown on PSMA-PET and mpMRI imaging
High-risk disease by NCCN criteria (cT3a or Grade group 4-5 or PSA > 20 ng/ml)
Signed informed consent
Age over 18 years
Completed PSMA-PET/CT, mpMRI or PSMA-PET/MR imaging
MMAI low or intermediate risk classification
ECOG performance status 0 or 1
IPSS score 15 or less
Available prostate biopsy core with highest ISUP grade
You will not qualify if you...
Prior radiotherapy to prostate or pelvis
Prior radical prostatectomy
Prior focal prostate therapy
Pelvic lymph node involvement (cN+) on imaging
Distant metastasis (cM+) on imaging
More than 2 months gap between systemic therapy start and PSMA-PET scans
cT4 disease on imaging
PSA over 50 ng/ml before systemic therapy
Expected survival less than 5 years
Bilateral hip prostheses or implants causing CT artifacts
Contraindications to MRI or HDR brachytherapy
Contraindications to Goserelin
Recent prostate surgery with significant tissue cavity or surgery within 6 months
Conditions making radiotherapy inadvisable (e.g., inflammatory bowel disease, paralysis)
Prior malignancy within 2 years except certain skin cancers
Other contraindications to pelvic external beam radiotherapy
Recent participation in other interventional trials
Unable to understand trial significance or legal incapacity
Known or ongoing substance abuse
Severe setup problems such as mental health conditions
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 12 months
Participants receive a high-dose-rate brachytherapy boost to the prostate, followed by stereotactic body radiation therapy to the prostate and seminal vesicles, along with 12 months of androgen deprivation therapy.
Multiple visits including treatment sessions and monitoring
Follow-up
Duration - Up to 5 years
Participants are monitored regularly through imaging, biopsies, quality of life assessments, and tests for treatment side effects and cancer control for up to five years after treatment.
Scheduled visits at 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months after treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Study of 4-Aminopyridine to Improve Nerve Recovery After Robot-Assisted Radical Prostatectomy in Men with Prostate Cancer
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Scans for Detecting Primary Prostate Cancer in Men
Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85
Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
Linda G W Kerkmeijer, Veerle H Groen, Floris J Pos...